Related references
Note: Only part of the references are listed.PCSK9 and LRP5 in macrophage lipid internalization and inflammation
Lina Badimon et al.
CARDIOVASCULAR RESEARCH (2021)
Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway
Xin Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation
Beili Xu et al.
FRONTIERS IN ONCOLOGY (2021)
Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome
Hideki Yano et al.
JOURNAL OF CARDIOLOGY (2020)
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up
Cristina Barale et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Blood flow patterns regulate PCSK9 secretion viaMyD88-mediated pro-inflammatory cytokines
Shijie Liu et al.
CARDIOVASCULAR RESEARCH (2020)
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Nicholas A. Marston et al.
CIRCULATION (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation
Vittoria Cammisotto et al.
ANTIOXIDANTS (2020)
An Update on the Role of PCSK9 in Atherosclerosis
Ece Yurtseven et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2020)
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Xinjian Liu et al.
NATURE (2020)
NLRP3 inflammasome via IL-1 13 regulates PCSK9 secretion
Zufeng Ding et al.
THERANOSTICS (2020)
PCSK9 inhibition and inflammation: A narrative review
Massimiliano Ruscica et al.
ATHEROSCLEROSIS (2019)
Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
Susanne Schuster et al.
SCIENTIFIC REPORTS (2019)
Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
Ye-Xuan Cao et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Effect of statins on measures of coagulation: potential role of low-density lipoprotein receptors
Francesco Paciullo et al.
EUROPEAN HEART JOURNAL (2019)
A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia
Young Uk Kim et al.
IMMUNE NETWORK (2019)
PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2018)
PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque
A. Liu et al.
JOURNAL OF INTERNAL MEDICINE (2018)
PCSK9 as a Positive Modulator of Platelet Activation
Marina Camera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseases
Anja Hofmann et al.
VASCULAR PHARMACOLOGY (2018)
Naringin Activates AMPK Resulting in Altered Expression of SREBPs, PCSK9, and LDLR To Reduce Body Weight in Obese C57BL/6J Mice
Guo-Guang Sui et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lipoprotein(a) a Risk Factor for Venous Thrombosis and Pulmonary Embolism in patients Younger Than 50 Years of Age
Sonha Nguyen et al.
BLOOD (2018)
Thrombophilia in 153 Patients With Premature Cardiovascular Disease ≤Age 45
Alexander Milgrom et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2018)
PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia
Sophie J. Bernelot Moens et al.
EUROPEAN HEART JOURNAL (2017)
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
Christine Landlinger et al.
EUROPEAN HEART JOURNAL (2017)
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
Eliano P. Nayarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
PCSK9 and Atherosclerosis - Lipids and Beyond
Michael D. Shapiro et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation
Daniele Pastori et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
Jiao Li et al.
MOLECULAR MEDICINE REPORTS (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-analysis of the Literature
Francesco Dentali et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2017)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
Hui Wang et al.
SCIENTIFIC REPORTS (2017)
Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages
Maria Pia Adorni et al.
ATHEROSCLEROSIS (2017)
PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
Petra El Khoury et al.
CURRENT ATHEROSCLEROSIS REPORTS (2017)
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Zhi-Han Tang et al.
ATHEROSCLEROSIS (2017)
Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin
Olga Panes et al.
ATHEROSCLEROSIS (2017)
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9
Nabil G. Seidah et al.
PHARMACOLOGICAL REVIEWS (2017)
Plasma L5 levels are elevated in ischemic stroke patients and enhance platelet aggregation
Ming-Yi Shen et al.
BLOOD (2016)
Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
Paul M. Ridker et al.
EUROPEAN HEART JOURNAL (2016)
Local effects of human PCSK9 on the atherosclerotic lesion
Ilaria Giunzioni et al.
JOURNAL OF PATHOLOGY (2016)
Cross-Talk Between PCSK9 and Damaged mtDNA in Vascular Smooth Muscle Cells: Role in Apoptosis
Zufeng Ding et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
Bertrand Cariou et al.
ATHEROSCLEROSIS (2016)
Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors
Karin Leander et al.
CIRCULATION (2016)
Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study
Wuxiang Xie et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Oxidized Low-Density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let-7c Is Integral to the Effect
Johan Frostegard et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
Eguzkine Ochoa et al.
PLOS ONE (2016)
Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
Zufeng Ding et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention
Yiming M. Zhu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Cross-talk between LOX-1 and PCSK9 in vascular tissues
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2015)
The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
Sha Li et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
K Domain CR9 of Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1) Is Critical for Aggregated LDL-induced Foam Cell Formation from Human Vascular Smooth Muscle Cells
Paula Costales et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lipopolysaccharide augments the uptake of oxidized LDL by up-regulating lectin-like oxidized LDL receptor-1 in macrophages
Ekhtear Hossain et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2015)
How it all starts: Initiation of the clotting cascade
Stephanie A. Smith et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2015)
Treating Atherosclerosis With Regulatory T Cells
Amanda C. Foks et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism
Roberto Carnevale et al.
ATHEROSCLEROSIS (2014)
Apolipoprotein E receptor-2 deficiency enhances macrophage susceptibility to lipid accumulation and cell death to augment atherosclerotic plaque progression and necrosis
Meaghan D. Waltmann et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
Mechanisms of Plaque Formation and Rupture
Jacob Fog Bentzon et al.
CIRCULATION RESEARCH (2014)
Pathophysiology of Acute Coronary Syndrome
Carlos G. Santos-Gallego et al.
CURRENT ATHEROSCLEROSIS REPORTS (2014)
Lipopolysaccharide Activates Toll-like Receptor 4 (TLR4)-mediated NF-κB Signaling Pathway and Proinflammatory Response in Human Pericytes
Irene Guijarro-Munoz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
Susan Kuhnast et al.
JOURNAL OF LIPID RESEARCH (2014)
Resistance and intolerance to statins
Z. Reiner
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
Gergana Galabova et al.
PLOS ONE (2014)
New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?
Amirhossein Sahebkar et al.
CARDIOVASCULAR DRUGS AND THERAPY (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
Maryssa Canuel et al.
PLOS ONE (2013)
The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
Steve Poirier et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in ldlr-/- mice fed on a high-fat diet
Gergana M. Deevska et al.
BIOSCIENCE REPORTS (2012)
Loss- and Gain-of-function PCSK9 Variants CLEAVAGE SPECIFICITY, DOMINANT NEGATIVE EFFECTS, AND LOW DENSITY LIPOPROTEIN RECEPTOR (LDLR) DEGRADATION
Suzanne Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo
Marie-Luise von Bruehl et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway
Chun-Yan Wu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2012)
Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages
Daniel Baitsch et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice
Kellie R. Machlus et al.
BLOOD (2011)
Unexpected roles for PCSK9 in lipid metabolism
Anne K. Soutar
CURRENT OPINION IN LIPIDOLOGY (2011)
Wnt pathway activation, cell migration, and lipid uptake is regulated by low-density lipoprotein receptor-related protein 5 in human macrophages
Maria Borrell-Pages et al.
EUROPEAN HEART JOURNAL (2011)
Mechanisms of LDL oxidation
Hiroshi Yoshida et al.
CLINICA CHIMICA ACTA (2010)
Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
Bin Dong et al.
JOURNAL OF LIPID RESEARCH (2010)
Extracellular DNA traps promote thrombosis
Tobias A. Fuchs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Endothelium, venous thromboembolism and ischaemic cardiovascular events
Paolo Gresele et al.
THROMBOSIS AND HAEMOSTASIS (2010)
PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
Bertrand Cariou et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells
Tommaso Fasano et al.
ATHEROSCLEROSIS (2009)
A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein
Kan Chen et al.
CIRCULATION RESEARCH (2008)
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
Janice Mayne et al.
LIPIDS IN HEALTH AND DISEASE (2008)
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Holly E. Careskey et al.
JOURNAL OF LIPID RESEARCH (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain
Eric N. Hampton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling - Molecular, cellular, and vascular behavior
Yiannis S. Chatzizisis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak
Simon N. Willis et al.
SCIENCE (2007)
Macrophage low-density lipoprotein receptor-related protein deficiency enhances atherosclerosis in ApoE/LDLR double knockout mice
L. Hu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Bcl-2 phosphorylation by p38 MAPK - Identification of target sites and biologic consequences
Giovanna De Chiara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c
P Costet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Circulating endothelial progenitor cells and cardiovascular outcomes
N Werner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo
N Bovenschen et al.
BLOOD (2005)
Toll-like receptors in innate immunity
K Takeda et al.
INTERNATIONAL IMMUNOLOGY (2005)
Elevated levels of FVIII : C within families are associated with an increased risk for venous and arterial thrombosis
I Bank et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins
F Tsuruta et al.
EMBO JOURNAL (2004)
Neutrophil extracellular traps kill bacteria
V Brinkmann et al.
SCIENCE (2004)
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
KM Timms et al.
HUMAN GENETICS (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells
V Llorente-Cortés et al.
CIRCULATION (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency
N Bovenschen et al.
BLOOD (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery
N Donovan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Sterol-regulatory element-binding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia
AR Miserez et al.
ATHEROSCLEROSIS (2002)
Modulation of Bcl-2 family proteins in primary endothelial cells during apoptosis
G Molostvov et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2002)
Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis
KJ Williams
CURRENT OPINION IN LIPIDOLOGY (2001)
Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation
C Martínez et al.
THROMBOSIS AND HAEMOSTASIS (2001)
Identification of the platelet ADP receptor targeted by antithrombotic drugs
G Hollopeter et al.
NATURE (2001)
Share Paper
